NASDAQ:LJPC - La Jolla Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.93 +0.09 (+1.54 %)
(As of 02/22/2019 02:04 AM ET)
Previous Close$5.84
Today's Range$5.81 - $5.9616
52-Week Range$5.01 - $38.39
Volume512,899 shs
Average Volume1.22 million shs
Market Capitalization$155.57 million
P/E Ratio-1.10
Dividend YieldN/A
Beta1.24
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. The company is developing LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$620,000.00
Book Value$3.68 per share

Profitability

Net Income$-114,800,000.00

Miscellaneous

Employees309
Market Cap$155.57 million
Next Earnings Date2/28/2019 (Estimated)
OptionableOptionable

La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) posted its earnings results on Wednesday, October, 24th. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($2.01) by $0.08. The biopharmaceutical company earned $3.47 million during the quarter, compared to the consensus estimate of $3.38 million. View La Jolla Pharmaceutical's Earnings History.

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for La Jolla Pharmaceutical.

What price target have analysts set for LJPC?

5 equities research analysts have issued 12-month price objectives for La Jolla Pharmaceutical's stock. Their predictions range from $6.00 to $115.00. On average, they anticipate La Jolla Pharmaceutical's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 490.2% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical.

What is the consensus analysts' recommendation for La Jolla Pharmaceutical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for La Jolla Pharmaceutical.

What are Wall Street analysts saying about La Jolla Pharmaceutical stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (1/17/2019)
  • 2. HC Wainwright analysts commented, "We are reducing our price target to $25, from $48, due to lower Giapreza sales expectations partially offset by cost cutting expectations in R&D and SG&A. We base our $25 price target on a sum-of-the-parts analysis based on: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year- end fully diluted net cash of $4.03/share, which includes the capital raise earlier this year and the royalty agreement, to arrive at our price target. We value the current commercial business at $9.82 per share and the pipeline at $10.83 per share." (1/9/2019)

Has La Jolla Pharmaceutical been receiving favorable news coverage?

Headlines about LJPC stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. La Jolla Pharmaceutical earned a media sentiment score of 2.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the immediate future.

Are investors shorting La Jolla Pharmaceutical?

La Jolla Pharmaceutical saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 6,730,140 shares, a drop of 21.5% from the December 31st total of 8,576,674 shares. Based on an average daily volume of 2,688,976 shares, the short-interest ratio is presently 2.5 days. Approximately 27.1% of the shares of the company are sold short. View La Jolla Pharmaceutical's Current Options Chain.

Who are some of La Jolla Pharmaceutical's key competitors?

What other stocks do shareholders of La Jolla Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other La Jolla Pharmaceutical investors own include Juno Therapeutics (JUNO), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Exelixis (EXEL), Celgene (CELG), Micron Technology (MU), Bausch Health Companies (BHC) and Advanced Micro Devices (AMD).

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the folowing people:
  • Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)
  • Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)
  • Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)
  • Mr. James M. Rolke, Chief Scientific Officer (Age 50)
  • Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48)

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (12.46%), Broadfin Capital LLC (7.42%), Sectoral Asset Management Inc (6.71%), BlackRock Inc. (5.71%), Millennium Management LLC (1.87%) and Prudential Financial Inc. (1.36%). Company insiders that own La Jolla Pharmaceutical stock include Dennis Mulroy, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.

Which institutional investors are selling La Jolla Pharmaceutical stock?

LJPC stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Broadfin Capital LLC, Oak Ridge Investments LLC, Squarepoint Ops LLC, Jennison Associates LLC, MetLife Investment Advisors LLC, Northern Trust Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for La Jolla Pharmaceutical.

Which institutional investors are buying La Jolla Pharmaceutical stock?

LJPC stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Fosun International Ltd, Sectoral Asset Management Inc, Citigroup Inc., Prudential Financial Inc., Ontario Teachers Pension Plan Board, GSA Capital Partners LLP and Emory University. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Dennis Mulroy, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $5.93.

How big of a company is La Jolla Pharmaceutical?

La Jolla Pharmaceutical has a market capitalization of $155.57 million and generates $620,000.00 in revenue each year. The biopharmaceutical company earns $-114,800,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis. La Jolla Pharmaceutical employs 309 workers across the globe.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is http://www.lajollapharmaceutical.com.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]


MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel